After an initial fundraising of €4 M in 2014, Hémarina (Morlaix, 40 employees) is raising more than €8 M from its historic partners (Finistère Angels, Armor Angels, XMP/Business Angels des Grandes Ecoles and the CM-CIC) as well as from new French and European shareholders among them health professionals, company heads, several Family offices and the Finistère investment fund Force 29.
Its CEO, F. Zal, is looking forward to speeding up research programmes, particularly for its HemoxyCarrier product, which targets ischemic diseases. The company should also perform a new large scale clinical trial for Hemo2life used to supplement transplant organ preservation solutions. This should be marketed in 2018 or 2019 and is also the subject of negotiations for distribution in Europe. As for its oxygenating HemHealing dressing, it should soon be the subject of a license agreement. Hémarina has a technical sales subsidiary in Boston, a raw materials production subsidiary in Noirmoutier and offices in Paris.
Source : Journal des Entreprises – 10/03/2017